Boehringer announced it will acquire Amgen's Fremont manufacturing site to further extend its global contract development and manufacturing capability for biologics. The Fremont site came to Amgen via its acquisition of Abgenix for $2.2 B in 2006. The Fremont site is 100,000 sq ft and houses 360 employees. It has previous experience producing panitumumab, Vectibix, commercially.
The acquistion enhances Boehringer's global footprint. It adds capability to its main manufacturing site in Biberach, Germany, and manufacturing and development partnerships that it has with Avid Bioservices and Kemwell in India. Financial terms of the Boehringer acquisition were not released but the company is supposed to take over the site formally in March.
Posted by Bruce Lehr January 20th 2011.